Clinical Trials Search Results Display: Title Description with: Locations Eligibility Full Trial Description Custom ? Hide Search Criteria Show Search Criteria Cancer Type/Condition: Pancreatic cancerTrial Type: Treatment Results 1-25 of 189 for your search: Start Over Select All on Page Sort by: Phase of Trial Title Type of Trial Status of Trial Age Range Trial ID Show 10 25 50 100 200 Results per Page 1. Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer Status: ActivePhase: Phase IVType: TreatmentAge: 18 and overTrial IDs: 90914721, NCI-2016-00348, CDM00047339, E7059, NCT01774019 2. A Phase 3 Study to Compare Efficacy and Safety of Masitinib in Combination With Gemcitabine, to Placebo in Combination With Gemcitabine, in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer Status: Temporarily closedPhase: Phase IIIType: TreatmentAge: 18 and overTrial IDs: AB07012, NCI-2013-01292, NCT00789633 3. Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery Status: ActivePhase: Phase IIIType: Biomarker/Laboratory analysis, TreatmentAge: 18 and overTrial IDs: RTOG-0848, NCI-2011-01987, CDR0000659092, NCT01013649 4. Surgery With or Without Intraperitoneal Drainage in Improving Complication Rate in Patients With Pancreatic Disease Status: ActivePhase: Phase IIIType: Health services research, TreatmentAge: 18 and overTrial IDs: H-28324, NCI-2012-01881, NCT01441492 5. Combination Chemotherapy with or without Stereotactic Body Radiation Therapy in Treating Patients with Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery Status: ActivePhase: Phase IIIType: Biomarker/Laboratory analysis, TreatmentAge: Over 18Trial IDs: PANC0015, NCI-2013-01658, 5136, NCT01926197 6. Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer Status: ActivePhase: Phase IIIType: TreatmentAge: 18 and overTrial IDs: EP-GF-301, NCI-2013-02181, NCT01954992 7. Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Status: ActivePhase: Phase IIIType: TreatmentAge: 18 and overTrial IDs: D081FC00001, NCI-2015-00038, 2014-001589-85, NCT02184195 8. Endoscopic Biliary Stent Placement with or without Radiofrequency Ablation in Treating Patients with Biliary Obstruction Arising From Pancreatic Cancer That Cannot Be Removed by Surgery Status: ActivePhase: Phase IIIType: TreatmentAge: 18 and overTrial IDs: 14-260, NCI-2015-00110, NCT02340728 9. A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Status: ActivePhase: Phase IIIType: TreatmentAge: 18 and overTrial IDs: HALO-109-301, NCI-2016-00854, 2015-004068-13, NCT02715804 10. A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Status: ActivePhase: Phase IIIType: TreatmentAge: 18 and overTrial IDs: CanStem111P, NCI-2017-00144, NCT02993731 11. Study of AM0010 With FOLFOX Compared to FOLFOX Alone Second-line Tx in Pts With Metastatic Pancreatic Cancer Status: ActivePhase: Phase IIIType: TreatmentAge: 18 and overTrial IDs: AM0010-301, NCI-2017-00276, NCT02923921 12. A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Status: ActivePhase: Phase II, Phase IType: TreatmentAge: 18 and overTrial IDs: BBI608-201, NCI-2014-01566, NCT01325441 13. Stereotactic Body Radiation Therapy in Treating Patients with Pancreatic or Ampulla of Vater Cancer That Cannot Be Removed by Surgery Status: ActivePhase: Phase II, Phase IType: TreatmentAge: 18 and overTrial IDs: 16866B, NCI-2015-01656, NCT01342354 14. Veliparib and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer Status: ActivePhase: Phase II, Phase IType: Biomarker/Laboratory analysis, TreatmentAge: 18 and overTrial IDs: 2009-608, NCI-2013-00656, NCT01489865 15. A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer Status: ActivePhase: Phase II, Phase IType: Biomarker/Laboratory analysis, TreatmentAge: 18 and overTrial IDs: UPCC 19211, NCI-2012-00026, NCT01506973 16. Genetically Engineered Lymphocytes in Treating Patients with Metastatic Cancer or Cancer That Cannot Be Removed by Surgery Receiving Chemotherapy and Aldesleukin Status: ActivePhase: Phase II, Phase IType: TreatmentAge: 18 to 66Trial IDs: 12-C-0111, NCI-2013-01516, 1112-1139, 120111, P11928, RD-12-I-02, NCT01583686 17. Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers Status: ActivePhase: Phase II, Phase IType: TreatmentAge: 18 and overTrial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552 18. Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer Status: ActivePhase: Phase II, Phase IType: Supportive care, TreatmentAge: 18 and overTrial IDs: 201404101, NCI-2013-00650, NCT01790035 19. Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA) Status: ActivePhase: Phase II, Phase IType: Biomarker/Laboratory analysis, TreatmentAge: Over 18Trial IDs: PCRT 12-001, NCI-2017-00689, NCT01893801 20. A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors Status: ActivePhase: Phase II, Phase IType: TreatmentAge: 18 and overTrial IDs: CA209-032, NCI-2013-02337, 2013-002844-10, NCT01928394 21. A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Status: ActivePhase: Phase II, Phase IType: Biomarker/Laboratory analysis, TreatmentAge: 18 and overTrial IDs: BBI608-246, NCI-2015-00892, NCT02024607 22. Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Status: ActivePhase: Phase II, Phase IType: Biomarker/Laboratory analysis, TreatmentAge: 18 and overTrial IDs: NLG2104, NCI-2014-02095, NCT02077881 23. Trametinib and Navitoclax in Treating Patients with Advanced or Metastatic Solid Tumors Status: ActivePhase: Phase II, Phase IType: Biomarker/Laboratory analysis, TreatmentAge: 18 and overTrial IDs: 9525, NCI-2014-00461, 13-505, NCT02079740 24. Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Metastatic Pancreatic Cancer Status: ActivePhase: Phase II, Phase IType: Biomarker/Laboratory analysis, TreatmentAge: 19 and overTrial IDs: 2013-133, NCI-2014-01249, 1403012942, NCT02178436 25. Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride with or without WEE1 Inhibitor MK-1775 in Treating Patients with Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery Status: Temporarily closedPhase: Phase II, Phase IType: Biomarker/Laboratory analysis, TreatmentAge: 18 and overTrial IDs: EA2131, NCI-2014-01425, E1213, NCT02194829 Select All on Page 1 Start Over